NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
LEQSELVI (deuruxolitinib phosphate) by PharmaIN is (jak) inhibitor. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQSELVI (deuruxolitinib phosphate) is an oral JAK inhibitor that selectively targets JAK1, JAK2, and TYK2 to modulate cytokine and growth factor signaling critical for immune function. The drug was approved by the FDA on July 25, 2024, and represents a novel therapeutic approach in the JAK inhibitor class. Patient indications and specific therapeutic uses have not yet been publicly disclosed.
Growth18.4 years to LOE
Early-stage growth product with significant runway; commercial teams are likely expanding to support market penetration and indication expansion.
Mechanism of Action
(JAK) inhibitor. JAKs mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEQSELVI is a newly launched JAK inhibitor in its growth phase with significant opportunity for team expansion and career development. The 18.5-year patent exclusivity and lack of direct documented competitors create a favorable environment for roles focused on market building, indication expansion, and managed markets access.
Brand Manager
Worked on LEQSELVI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.